For research use only. Not for therapeutic Use.
Letrozole-d4 (CAS: 1133712-96-5), a premium pharmaceutical research compound designed for advanced oncology and endocrine studies. As a deuterated analog of Letrozole, it offers enhanced stability and improved pharmacokinetic properties. Letrozole-d4 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for hormone receptor-positive breast cancer and other estrogen-dependent conditions. Trusted by leading laboratories, Letrozole-d4 is your go-to solution for cutting-edge cancer research. Unlock new possibilities in hormonal cancer treatment with Letrozole-d4, where innovation meets reliability.
| Catalog Number | S000169 |
| CAS Number | 1133712-96-5 |
| Molecular Formula | C17H7D4N5 |
| Purity | ≥95% |
| Target | Autophagy |
| IUPAC Name | 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]-2,3,5,6-tetradeuteriobenzonitrile |
| InChI | InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H/i1D,2D,5D,6D |
| InChIKey | HPJKCIUCZWXJDR-NMRLXUNGSA-N |
| SMILES | [2H]C1=C(C(=C(C(=C1C#N)[2H])[2H])C(C2=CC=C(C=C2)C#N)N3C=NC=N3)[2H] |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Bhatnagar AS, et, al. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1021-7. [3]. Mitropoulou TN, et, al. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer. 2003 Mar 20;104(2):155-60. [4]. Schieweck K, et, al. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):633-6. |
